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In the present study, we tested the hypothesis that selective activation of estrogen receptor subtypes (ERα and ERβ)w o u l db e
neuroprotective following ischemia and/or ischemia-reperfusion, as well as prevent the associated autonomic dysfunction. The
selective ERα agonist, PPT, when administered 30min prior to occlusion of the middle cerebral artery (pMCAO), resulted in a
dose-dependent neuroprotection as measured 6 hours postpermanent MCAO, but not following 30mins of MCAO followed by
5.5hrs of reperfusion (I/R). In contrast, 30min pretreatment with the selective ERβ agonist, DPN, resulted in a dose-dependent
neuroprotection following I/R, but was not protective following pMCAO. Both drugs prevented the ischemia-induced autonomic
dysfunction as measured by a decrease in the baroreceptor reﬂex sensitivity (BRS). The data presented here suggest a diﬀerential
role of each ER subtype in targeting the mechanisms of cell death that occur in ischemia versus reperfusion injury.
1.Introduction
The use of estrogen as a therapeutic agent in neurodegen-
erative diseases, in particular stroke, has been investigated
over the last decade. Our laboratory, as well as several
others,havedemonstratedthatestrogen signiﬁcantlyreduces
ischemia-induced cell death following middle cerebral artery
occlusion (MCAO) using multiple rodent models of per-
manent and transient ischemic stroke [1–5]. Unfortunately,
this success against ischemic cell death observed in such
preclinical studies following administration of estrogen to
animals has not translated to successful clinical trial results
in humans [6].Althoughitisdebatableifsome oftheclinical
trial designs hold validity [7, 8], many researchers remain
convinced that estrogen, or some intermediate molecular
target(s) of estrogen, play a key role in neuroprotection
followingischemicstroke,andischemia-reperfusion (I/R)[9,
10]. As a result, many current investigations have examined
the mechanism of estrogen-induced neuroprotection.
Estrogen has been shown to result in both rapid and
acute as well as long-term, chronic alterations in neuronal
physiology, and this may be due to diﬀerential activation of
estrogen receptor (ER) subtypes, one of which may reside
on the cell membrane. Two main estrogen receptor subtypes
have been identiﬁed, ERα,E R β, and the putative membrane-
bound receptor GPR30 [11]. To date, the issue of which
ER subtype plays a predominant role in estrogen-mediated
neuroprotection has not been resolved. These studies suggest
that both ERα and ERβ receptor subtypes are expressed in
the cerebral cortex in adult rats [12, 13]. Several laboratories
have proposed that the ERα receptor subtype is more impor-
tant in estrogen-mediated neuroprotectionin animal models
of cerebral ischemia [14–16]. Merchenthaler and colleagues
[14] determined that ERα was responsible for mediating
the neuroprotectiveactions of estrogen following permanent
MCAO. These authorsalso demonstrated that the penumbra
contained a large number of immunoreactive and mRNA-
expressing ERα positive cells, and this was only observed2 Advances in Pharmacological Sciences
on the ipsilateral, but not the contralateral side. Further
support for the neuroprotective eﬀects of ERα comes from
Dubalandcolleagues[15]whoreportedthatdeletionofERβ,
using ERβ knockout mice, had no eﬀect on the estrogen-
induced protection following ischemia, whereas the protec-
tive actions of estrogen were completely abolished in ERα
knockoutmice. In a more recent study, Dubal and colleagues
[16] investigated the temporal expression of ERα following
permanent MCAO and reported a signiﬁcant induction of
ERα mRNA in the ischemic region early in the development
of the infarct. In contrast, Farr and colleagues [17]d i dn o t
observe a neuroprotective eﬀect of ERβ activation in a rat
model of permanent focal ischemia. However, activation of
ERβ has been shown to promote neuroprotection against
glutamate excitotoxicity in hippocampal neurons [18].
Our laboratory has previously demonstrated that sys-
temic estrogen administration signiﬁcantly enhanced auto-
n o m i cf u n c t i o na sm e a s u r e db ya ni n c r e a s ei nt h es e n s i t i v i t y
ofthebaroreceptorreﬂex (BRS)inboth male and female rats
[19–22]. Further, we have demonstrated that estrogen acts
centrally to improve sympathovagal balance by decreasing
sympathetic tone and increasing parasympathetic tone [23–
25]. The BRS is depressed following the onset of several
cardiovascular pathologies [26, 27] including stroke and
the administration of systemic estrogen has been shown to
decrease both the stroke-induced depression in the BRS and
stroke-induce ischemia [4].
The aim of these experiments is to determine if a
dichotomy exists between the ability of ERα or ERβ receptor
subtypesto mediate neuroprotectioninboth permanent and
transient models of cerebral ischemia in a single study. Also,
we set out to determine if selective ER receptor agonists also
mediate protection against the stroke-induced autonomic
dysfunctionasmeasuredbytheischemia-induceddepression
in the sensitivity of the BRS.
2.Methods
All experiments were carried out in accordance with the
guidelinesoftheCanadianCouncilonAnimalCareandwere
approved by the University of Prince Edward Island Animal
Care Committee.
2.1. General Surgical Procedures. All experiments were con-
ducted on male Sprague-Dawley rats (90 rats; 250–350g;
Charles Rivers; Montreal, PQ, Canada). For all animals,
food and tap water were available ad libitum.R a t sw e r e
anaesthetized with sodium thiobutabarbital(Inactin; Sigma-
Aldridge;St.Louis,MO,USA;100mg/kg;ip)whichprovided
a stable plane of anesthesia for the full duration of the
experimental time periods (no animals required anesthetic
supplementation).Tomonitorbloodpressure andheart rate,
a polyethylene catheter (PE-50; Clay Adams, Parsippany,
NJ, USA) was inserted into the right femoral artery. For
intravenous administration of drugs, a polyethylene catheter
(PE-10; Clay Adams, Parsippany, NJ, USA) was inserted into
the right femoral vein. Arterial blood pressure was measured
with a pressure transducer (Gould P23 ID, Cleveland, OH)
connected to a Gould model 2200S polygraph. Heart rate
wasdeterminedfromthepulsepressureusingaGouldtacho-
graph (Biotach). These parameters were displayed and ana-
lyzed using PolyviewPro/32 data acquisition and analysis
software (Grass; Warwick, RI, USA). An endotracheal tube
was inserted to facilitate spontaneous breathing on room
air. Body temperature was monitored and maintained at
37 ± 1◦C using a Physitemp feedback system (Physitemp
Instruments; Clifton, NJ, USA).
4,4 ,4  -(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol
(PPT; Tocris Bioscience) and 2,3-bis(4-hydroxyphenyl)-
propionitrile (DPN; Tocris Bioscience) were used to select-
ively activate estrogen alpha (ERα)a n db e t a( E R β) receptors,
respectively.
2.2. Middle Cerebral Artery Occlusions (MCAO). Our labhad
previously published the detailed methodology for transient
occlusion of the middle cerebral artery [1]. Brieﬂy, animals
were placed in a David Kopf stereotaxic frame (Tujunga,
CA, USA) and the right middle cerebral artery (MCA)
approached through a rostral-caudal incision of the skin and
frontalis muscle at the approximate level of bregma. Blood
ﬂow through the MCA was impeded by the placement of
surgical suture behind the MCA at 3 designated positions
along the exposed vessel. The ends of the sutures were
positioned so that the middle of the each suture applied
pressure to the MCA and impeded blood ﬂow. This 3-
point placement of surgical sutures produced a highly
reproducible and consistent focal ischemic lesion restricted
to the ipsilateral cerebral cortex. To facilitate removal of the
sutures at the end of the occlusion period (30 minutes),
a few drops of warm physiological saline (37◦C) was ﬁrst
applied to the areas where the MCA was in contact with
the sutures. Blood was allowed to reperfuse the area for an
additional 5.5 hours (I/R).At the endof the6 hour occlusion
(pMCAO) or I/R, all animals were perfused transcardially
with phosphate buﬀered saline (PBS; 0.1M; 200mls), the
brainsremovedandslicedinto1mmcoronalsectionsusinga
rat brain matrix (Harvard Apparatus; Holliston, MA, USA).
2.3. Cardiac Baroreﬂex Testing. To determine the eﬀect of
estrogenic agonists and MCAO or I/R on the reﬂex brady-
cardia following baroreceptor activation, the baroreceptor
reﬂex was evoked using a bolus intravenous injection of the
α-adrenergic receptor agonist phenylephrine-hydrochloride
(Sigma-Aldridge; 0.1mL; 2.5μg/mL; iv). The ratio of the
peakchange in themagnitudeofthereﬂex bradycardia tothe
magnitude of the phenylephrine-induced pressor response
(ΔHR/ΔMAP) was used as a measure of BRS. The BRS was
tested using PE injected at 10min intervals prior to drug
injection and MCAO and then at regular intervals following
occlusion and/or reperfusion.
2.4. Eﬀect of PPT and DPN on Permanent or Reperfusion-
Induced Infarct Volume. In the ﬁrst experiment, to examine
the eﬀect of estrogen receptor alpha activation on both
permanent ischemia and ischemia-reperfusion-induced cell
death, injections of PPT (0.01, 0.05, 0.1, or 1.0mg/kg;Advances in Pharmacological Sciences 3
1mL/kg; iv; n = 4/group) or dimethyl sulfoxide (DMSO;
50%; 1mL/kg; iv; n = 4) were made 30 minutes (−30
minutes) prior to MCAO. In the ﬁrst group, the sutures
were left in place for 30 minutes, followed by 5.5 hours of
reperfusion (I/R). In the second group, the sutures were left
in place for 6 hours (pMCAO).The cardiac BRS was tested at
10min intervals prior to and during pMCAO and I/R. In the
secondexperiment,toexaminetheeﬀectofestrogenreceptor
beta activation on both permanent ischemia and ischemia-
reperfusion-induced cell death, injections of DPN (0.01, 0.1,
or 1.0mg/kg; 1mL/kg; iv; n = 4 to 6/group) or dimethyl
sulfoxide (DMSO; 7.5%; 1mL/kg; iv; n = 6) were made 30
minutes (−30 minutes) prior to pMCAO or I/R. The cardiac
BRS was tested as described above.
2.5. Histological Procedures. Sections were incubated in a
2% solution of 2,3,5-triphenol tetrazolium chloride (TTC;
Sigma-Aldrich; St. Louis; MO, USA) for 5 minutes. Infarct
volumes were calculated with the use of scanned digital
images of each brain section. Infarct areas were calculated
using a computer-assisted imaging system (Scion Corpora-
t i o n ;F r e d e r i c k ,M D ,U S A ) .T h ei n f a r c ta r e a sf o re a c hs i d e
for each individual section were averaged and multiplied by
the width of each section (1mm) to give the infarct volume
for each section. The sum total of all the individual infarct
volumes provided the infarct volume for each rat.
2.6.Statistical Analysis. Data were analyzed using a statistical
software package (SigmaStat and SigmaPlot; Jandel Scien-
tiﬁc, Tujunga, CA, USA). All data are presented as a mean
± standard error of the mean (S.E.M.). Diﬀerences were
considered statistically signiﬁcant if P ≤ .05 by an analysis
of variance (ANOVA) followed by a Bonferroni post-hoc
analysis or repeated measures (BRS). When only two groups
were being compared the Student’s t-test was used.
3.Results
3.1. The Eﬀect of Administration of PPT on Infarct Volume
Following Permanent MCAO and I/R. The following exper-
iment was designed to determine the eﬀect of the estrogen
receptor alpha (ERα) agonist, PPT, on pMCAO and I/R.
30min pretreatment with PPT followed by I/R did not
produce signiﬁcant neuroprotection compared to vehicle
(P ≥ .05; Figure 1(a)). In contrast, pretreatment with PPT
prior to 6 hours of pMCAO resulted in a dose-dependent
neuroprotection, with doses of 0.1 and 1.0mg/kg resulting
in a signiﬁcant decrease in infarct volume compared to the
administration of vehicle (P ≤ .05; Figures 1(b) and 1(c)).
3.2. The Eﬀect of Administration of DPN on Infarct Volume
Following Permanent MCAO and I/R. The following exper-
iment was designed to determine the eﬀect of the estrogen
receptor beta (ERβ) agonist, DPN, on pMCAO-induced
ischemia and I/R. DPN (1.0mg/kg) produced signiﬁcant
neuroprotection compared to vehicle when administered 30
minutes prior to I/R (P ≤ .05; Figures 2(a) and 2(c)). In
contrast, DPN pretreatment prior to 6 hours of pMCAO did
not result in signiﬁcant neuroprotection compared to the
administration of vehicle (P ≥ .05; Figure 2(b)).
3.3. The Eﬀect of Preadministration of PPT on Cardiovascular
and Autonomic Parameters. The following experiment was
designed to determine the eﬀect of preadministration of a
neuroprotective dose of PPT (1.0mg/kg) on blood pressure,
heart rate, and BRS before and during 6 hours of pMCAO.
Preadministration of PPT or vehicle (50% DMSO) did not
signiﬁcantly alter mean arterial blood pressure or mean
heart rate prior to, during, or following occlusion (P ≥
.05 compared to pre-pMCAO values, Figures 3(a), 3(b) and
3(c)). In the vehicle treated group, there was a signiﬁcant
decrease in BRS from 10mins post-pMCAO to the end of
the experiment (6 hours post-pMCAO; P ≤ .05 for each
time point; Figure 3(d)). Administration of PPT completely
blocked the depression in BRS at all time intervals measured
post-pMCAO (P ≥ .05; for each time point compared to
baseline and vehicle at the same time point; Figure 3(d)).
3.4. The Eﬀect of Preadministration of DPN on Cardiovascu-
lar Parameters. The following experiment was designed to
determine the eﬀect of preadministration of a neuroprotec-
tive dose of DPN (1.0mg/kg) on blood pressure, heart rate,
and BRS before and following 30 minutes of MCA occlusion
followedby5.5hoursofreperfusion(I/R).Preadministration
of DPN or vehicle (7.5% DMSO) did not signiﬁcantly alter
mean arterial blood pressure or mean heart rate prior to,
during, or following occlusion (P ≥ .05; Figures 4(a),
4(b),a n d4(c)). In the vehicle-treated group, BRS decreased
signiﬁcantly both during MCAO (30mins) and immediately
following reperfusion ()I/R) and continued depressed for
the remained of the experiment (P ≤ .05; for each time
point; Figure 4(d)). Administration of DPN 30mins prior
to MCAO completely blocked this depression of the BRS
during both the 30mins of ischemia as well as the 5.5 hours
of reperfusion. The BRS remained not signiﬁcantly diﬀerent
from baseline values measured prior to DPN administration
for the full 5.5 hours post-MCAO (P ≥ .05; for each time
point; Figure 4(d)).
4.Discussion
The results ofthe present investigation suggest that the selec-
tiveactivationoftheestrogenreceptorsubtypes,ERαorERβ,
diﬀerentially provide neuroprotection within the cerebral
cortex against occlusive and reperfusion injury, respectively,
as seen following permanent or transient MCAO. Our
observations suggest that within the initial 6 hours following
an ischemic insult, ERα protects against pMCAO-induced
cell death only, while ERβ provides neuroprotection against
I/R-induced cell death only. Further, activation of either ERα
or ERβ can prevent the depression in the BRS observed
following either pMCAO or I/R. These results suggest that
estrogen receptor subtypes play diﬀerent roles in protecting
against the cell death associated with ischemia versus reper-
fusion injury; however, either receptor can participate in the
prevention of the stroke-induced autonomic dysfunction.4 Advances in Pharmacological Sciences
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Figure 1: Eﬀect of pretreatment with either 50% DMSO or PPT (i.v.; 30 minutes) on infarct volume (mm3)c a l c u l a t e df r o mT T C - s t a i n e d
1mmthickcoronalsectionsthroughouttheextentoftheinfarctfollowingI/R(a)andMCAO(b).Eachbarrepresents themean±S.E.M(n=
4–6/group), and ∗indicates signiﬁcance (P ≤ .05) from the DMSO control group. (c) Representative photomicrographs of TTC stained,
1mm thick coronal slices illustrating the extent of the infarct within the prefrontal cortex following 30 minutes pretreatment (i.v.) with
either DMSO or PPT (1mg/kg) at 6 hours post-MCAO.
The exact eventsthat lead from ischemia to cell death are
not fully understood. However, convincing evidence sup-
ports the suggestion that excitotoxicity follows the hypoxic
and hypoglycemic conditions following stroke [28]. Estro-
gen has been shown to protect against ischemia-induced
excitotoxic injury in various in vivo and in vitro models of
stroke [3]. The exact mechanisms of estrogen-induced neu-
roprotection are still being studied by several laboratories,
including the role of estrogen receptor subtypes. Estrogen
has been demonstrated to be an eﬀective neuroprotectant in
similar models of both permanent and transient MCAO [1,
4]. The data presented here now demonstrate that activation
of the ERα subtype may have been responsible for the neu-
roprotective eﬀect of estrogen seen in the permanent MCAO
model, whereas activation of ERβ m a yp l a yam o r ep r o m i -
nent role in neuroprotection against reperfusion injury
following transient ischemia.
A prominent role for the ERα receptor subtype in estro-
gen-mediated neuroprotection in animal models of cerebral
ischemia has been well documented [14–16]. Our currentAdvances in Pharmacological Sciences 5
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Figure 2: Eﬀect of pretreatment with either 7.5% DMSO or DPN (i.v.; 30 minutes) on infarct volume (mm3)c a l c u l a t e df r o mT T C - s t a i n e d
1mmthickcoronalsectionsthroughouttheextentoftheinfarctfollowingI/R(a)andMCAO(b).Eachbarrepresents themean±S.E.M(n=
4–6/group), and ∗indicates signiﬁcance (P ≤ .05) from the DMSO control group. (c) Representative photomicrographs of TTC stained,
1mm thick coronal slices illustrating the extent of the infarct within the prefrontal cortex following 30 minutes pretreatment (i.v.) with
either DMSO or DPN (1mg/kg) at 6 hours post-I/R.
resultsare consistentwith this suggestionas theprioradmin-
istration of the ERα agonist, PPT, provided signiﬁcant
neuroprotection in our model of pMCAO, while the admin-
istration of the same dose ranges of the ERβ agonist,
DPN, was not able to provide signiﬁcant neuroprotection
against pMCAO-induced ischemia. Further evidence for this
suggestion was provided by Dubal and colleagues [15]w h o
reported that deletion of ERβ,u s i n gE R β knockout mice,
had no eﬀect on the estrogen-induced protection following
ischemia, whereas the protective actions of estrogen were
completely abolished in ERα knockout mice. This ﬁnding
was later supported by Dubal and colleagues [16] following
an investigation of the temporal expression of ERα following
pMCAO and reported a signiﬁcant induction of ERα mRNA
in the ischemic region within 4 hours of the development
of the infarct. In a study conducted by Merchenthaler
and colleagues [14], they demonstrated that the penumbra
contained a large number of ERα mRNA-expressing and
ERα-immunoreactive cells and this was only observed on
the ipsilateral, but not the contralateral side. Finally, Sampei
and colleagues [29] excluded a role for ERα involvement
in the estrogen-mediated neuroprotection observed in their6 Advances in Pharmacological Sciences
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Figure 3: Cardiovascular responses to PPT (1mg/kg) or 50% DMSO pretreatment (i.v.; 30 minutes) prior to MCAO. (a) Representative
physiograph tracings of changes in arterial pressure and heart rate to phenylephrine injection (PE; 2.5μg/mL). Graphs represent average
changesin meanarterial pressure (MAP;(b)),heart rate (HR; (c)),andbaroreceptor reﬂex sensitivity (BRS;(d)).The dashed linesrepresents
the times at which the MCA was occluded. Each data point represents the mean ± S.E.M (n = 4–6/group), and ∗indicates signiﬁcance
(P ≤ .05) from baseline values.
transient model of ischemia. These studies support our ob-
servation that ERα is responsible for mediating the neuro-
protective actions of estrogen following pMCAO.
Although a great deal of evidence supports the role of
ERα in estrogen-induced neuroprotection in animal models
of ischemia, ERβ has also been shown to mediate the beneﬁ-
cial eﬀectsofestrogen in the brain. Wang and colleagues[30]
demonstrated the importance of ERβ in neuronal survival
as developmental abnormalities occurred in ERβ knockout
m i c e .I na d d i t i o n ,a c t i v a t i o no fE R β using DPN was shown
to promote neuroprotection against glutamate excitotoxicity
inhippocampalneuronsinrats[18]andinamousemodelof
global ischemia [31]. We now report that selective activation
of ERβ resulted in neuroprotection in a transient MCAO
modelbutnotinapermanentmodelofMCAOinrats.These
results are in agreement with those published by Farr andAdvances in Pharmacological Sciences 7
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physiograph tracings of changes in arterial pressure and heart rate to phenylephrine injection (PE; 2.5μg/mL). Graphs represent average
changes in mean arterial pressure (MAP; (b)), heart rate (HR; (c)), and baroreceptor reﬂex sensitivity (BRS; (d)). The ﬁrst dashed lines
represents the times at which the MCA was occluded and the second line indicates when blood ﬂow was returned (reperfusion). Each data
point represents the mean ± S.E.M (n = 4–6/group), and ∗indicates signiﬁcance (P ≤ .05) from baseline values.
colleagues [17] who also did not observe a neuroprotective
eﬀect of ERβ activation in a rat model of permanent focal
ischemia.
During an occlusive episode, hypoxia and hypoglycemia
produce an ischemic core where failure of ATP-dependent
pumps lead to disruption of ionic equilibrium, calcium ho-
meostasis, excitotoxicity, and eventual cell death [32]. Rein-
troduction of blood ﬂow to underperfused neurons (e.g.,
with thrombolytic therapy) can result in reperfusion-injury
in neurons that are in anoxic compensation and lead to
the generation of toxic levels of oxidative free radicals
[33, 34] resulting in lipid peroxidation, protein synthesis
arrest, and cell death [34]. Estrogen has been shown to have
antioxidant capabilities [35], and this may suggest a mech-
anism by which estrogen mediates neuroprotection against
reperfusion-injury. It is possible that administration of the8 Advances in Pharmacological Sciences
ERβ agonist may act within the penumbra and ischemic
area as an antioxidant, or by increasing the cells antioxidant
capabilities, and this ability may or may not be related to
activation of the estrogen receptor subtype. Both an inves-
tigation of the molecular mechanisms mediating the ERβ-
induced neuroprotection as well as development of selective
ERβ antagonists will bebeneﬁcial in answering this question.
Clinically elevated sympathetic tone (sympathoexcita-
tion), depressed parasympathetic tone, and abnormal elec-
trocardiograms have been observed within 1 to 2 hours
following thrombolytic or hemorrhagic stroke involving the
MCA[36,37],andsuchautonomicdysfunctionincreasesthe
risk of sudden cardiac death [36, 37]. Arrhythmogenesis and
sudden cardiac death which can occur following pMCAO
in humans is associated with a depressed BRS [27]. Sym-
pathoexcitation [38] and a depressed BRS can be mimicked
in rat models of pMCAO [4]. Previous work from our lab-
oratory have demonstrated that the prior administration of
estrogen completely blocked the pMCAO-induced increase
in sympathetic tone and decrease in BRS [4]. Further, we
also demonstrated that this estrogen-mediated protection
against the pMCAO-induced autonomic dysfunction was
estrogen receptor dependent, as the eﬀect was blockedby the
priororconcomitantadministration oftheselectiveestrogen
receptor antagonist, ICI-182,780 [4]. We have demonstrated
in this study that prior administration of selective estrogen
receptor agonist for either ERα (PPT) or ERβ (DPN)
subtypes produced functional protection by blocking the
depression in the BRS observed following pMCAO and I/R.
The use of selective ERα and ERβ receptor antagonists will
allow usto conﬁrm if the functional protection observedwas
mediated via the selective activation of ERα or ERβ receptor
subtypesorthroughPPTand/orDPN-inducednonreceptor-
mediated eﬀects. Additional studies in our laboratory will
focus on the potential mechanism of this estrogen receptor
subtype activation in preventing the attenuated BRS. Pos-
sible options include an action directly on sympathetic or
parasympathetic preganglionic neurons in the brain and/or
spinalcord,anactiononsystemicarterialvasculatureoreven
a direct action on cardiac myocytes which have been shown
to express both estrogen receptor subtypes.
In the present study, we observed that the most eﬀective
dose of the ERα agonist PPT, and the ERβ agonist DPN, on
both neuroprotection and autonomic protection following
pMCAO or I/R was 1.0mg/kg, which is 100 times greater
thantheoptimaldoseof17β-estradiol(0.01mg/kg)observed
in similar studies in our laboratory [4, 5]. The greater dose
requirement of these selective agonists compared to estradiol
indicates that the activation of both receptor subtypes
at the same time by estradiol may produce a synergistic
eﬀect on the neuroprotective mechanisms activated or that
estradiol is a more potent antioxidant/free radical scavenger
(a nonreceptor-mediated eﬀect) that either selective agonist.
In conclusion, our results suggest that each estrogen
receptor subtype selectively and diﬀerentially protect against
permanent or reperfusion injury following MCAO in rats.
Also, we determined that both selective ERα and ERβ ago-
nists mediate functional protection against stroke-induced
autonomic dysfunction as measured by the depression in the
BRS.These results may provide insight into the development
of targeted therapeutic strategies against ischemia and I/R-
induced cell death and the subsequent cardiovascular conse-
quences following stroke.
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